Ulf Gyllensten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulf Gyllensten has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Dan Chen
Department of Immunology, Genetics and Pathology, Ministry of Education and Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 shared publications Annika Idahl
Department of Clinical Sciences, Obstetrics and Gynecology Umeå University SE‐901 87 Umeå Sweden
1 shared publicationBo Johanneson
Department of Immunology, Genetics and Pathology, SciLifeLab Uppsala, Biomedical center, Uppsala University, Box 815, Uppsala 75108, Sweden
1 shared publication- David Lindquist
Department of Radiation Sciences, Umeå University, Umeå, Sweden
1 shared publication Joanna Hammer
Department of Immunology, Genetics and Pathology Rudbeck Laboratory Science for Life Laboratory Uppsala Uppsala University SE‐751 85 Uppsala Sweden
1 shared publication- Stefan Enroth
Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala, Sweden
1 shared publication
Latest Publications
- Open Access
- 30 May 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (9) , 2084-2088
Systematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study
A large number of genetic associations with cervical cancer have been reported in hypothesis-driven candidate gene studies, but most studies have not included an independent replication or the results have been inconsistent between studies. In order to independently validate these associations, we reexamined 58 candidate gene/regions previously reported to be associated with cervical cancer using the gene-based Adaptive Rank Truncated Product test in a genome-wide association study (GWAS) of 1034 cervical cancer patients and 3948 controls from the Swedish population. Of the 58 gene/regions, 8 had a nominal P value < 0.05 [tumor necrosis factor (TNF), P = 5.0 × 10−4; DEAD (Asp-Glu-Ala-Asp) box helicase 1 [DDX1], P = 2.2 × 10−3; exonuclease 1 [EXO1], P = 4.7 × 10−3; excision repair cross-complementing rodent repair deficiency, complementation group 1 [ERCC1], P = 0.020; transmembrane channel-like 6 and 8 genes [TMC6-TMC8], P = 0.023; secreted phosphoprotein 1 [SPP1], P = 0.028; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2], P = 0.033 and chloride channel, voltage-sensitive 7 [CLCN7], P = 0.047). After correction for multiple testing, only TNF remained statistically significant (P = 0.028). Two single-nucleotide polymorphisms that are in nearly perfect linkage disequilibrium (rs2857602 and rs2844484) contributed most to the association with TNF. However, they are not independent from the previously reported associations within the MHC region. The very low number of previously reported associations with cervical cancer that replicate in the Swedish population underscore the need to apply more stringent criteria when reporting associations, including the prerequisite of replicating the association as part of the original study.
- 30 May 2014
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 35 (9) , 2084-2088
Open AccessSystematic validation of hypothesis-driven candidate genes for cervical cancer in a genome-wide association study
A large number of genetic associations with cervical cancer have been reported in hypothesis-driven candidate gene studies, but most studies have not included an independent replication or the results have been inconsistent between studies. In order to independently validate these associations, we reexamined 58 candidate gene/regions previously reported to be associated with cervical cancer using the gene-based Adaptive Rank Truncated Product test in a genome-wide association study (GWAS) of 1034 cervical cancer patients and 3948 controls from the Swedish population. Of the 58 gene/regions, 8 had a nominal P value < 0.05 [tumor necrosis factor (TNF), P = 5.0 × 10−4; DEAD (Asp-Glu-Ala-Asp) box helicase 1 [DDX1], P = 2.2 × 10−3; exonuclease 1 [EXO1], P = 4.7 × 10−3; excision repair cross-complementing rodent repair deficiency, complementation group 1 [ERCC1], P = 0.020; transmembrane channel-like 6 and 8 genes [TMC6-TMC8], P = 0.023; secreted phosphoprotein 1 [SPP1], P = 0.028; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2], P = 0.033 and chloride channel, voltage-sensitive 7 [CLCN7], P = 0.047). After correction for multiple testing, only TNF remained statistically significant (P = 0.028). Two single-nucleotide polymorphisms that are in nearly perfect linkage disequilibrium (rs2857602 and rs2844484) contributed most to the association with TNF. However, they are not independent from the previously reported associations within the MHC region. The very low number of previously reported associations with cervical cancer that replicate in the Swedish population underscore the need to apply more stringent criteria when reporting associations, including the prerequisite of replicating the association as part of the original study.
- Open Access
- 12 February 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (2) , 445-452
A cis‐eQTL of HLA‐DRB1 and a frameshift mutation of MICA contribute to the pattern of association of HLA alleles with cervical cancer
The association of classic human leukocyte antigen (HLA) alleles with risk of cervical cancer has been extensively studied, and a protective effect has consistently been found for DRB1*1301, DQA1*0103, and/or DQB1*0603 (these three alleles are in perfect linkage disequilibrium [LD] and often occur on the same haplotype in Europeans), while reports have differed widely with respect to the effect of HLA‐B*07, DRB1*1501, and/or DQB1*0602 (the last two alleles are also in perfect LD in Europeans). It is not clear whether the reported HLA alleles are responsible for the differences in cervical cancer susceptibility, or if functional variants at other locations within the major histocompatibility complex (MHC) region may explain the effect. In order to assess the relative contribution of both classic HLA alleles and single‐nucleotide polymorphisms (SNPs) within the MHC region to cervical cancer susceptibility, we have imputed classic HLA alleles in 1034 cervical cancer patients and 3948 controls in a Swedish population for an integrated analysis. We found that the protective haplotype DRB1*1301‐DQA1*0103‐DQB1*0603 has a direct effect on cervical cancer and always occurs together with the C allele of a HLA‐DRB1 cis‐eQTL (rs9272143), which increases the expression of HLA‐DRB1. The haplotype rs9272143C‐DRB1*1301‐DQA1*0103‐DQB1*0603 conferred the strongest protection against cervical cancer (odds ratio [OR] = 0.41, 95% confidence interval [CI] = 0.32–0.52, P = 6.2 × 10−13). On the other hand, the associations with HLA‐B*0702 and DRB1*1501‐DQB1*0602 are attributable to the joint effects of both the HLA‐DRB1 cis‐eQTL (rs9272143) and a frameshift mutation (G inserion of rs67841474, also known as A5.1) of the MHC class I polypeptide‐related sequence A gene (MICA). Variation in LD between the classic HLA loci, rs9272143 and rs67841474 between populations may explain the different associations of HLA‐B*07 and DRB1*1501‐DQB1*0602 with cervical cancer between studies. The mechanism suggested may also explain similar inconsistent results for other HLA‐associated diseases.
- 12 February 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (2) , 445-452
Open AccessA cis‐eQTL of HLA‐DRB1 and a frameshift mutation of MICA contribute to the pattern of association of HLA alleles with cervical cancer
The association of classic human leukocyte antigen (HLA) alleles with risk of cervical cancer has been extensively studied, and a protective effect has consistently been found for DRB1*1301, DQA1*0103, and/or DQB1*0603 (these three alleles are in perfect linkage disequilibrium [LD] and often occur on the same haplotype in Europeans), while reports have differed widely with respect to the effect of HLA‐B*07, DRB1*1501, and/or DQB1*0602 (the last two alleles are also in perfect LD in Europeans). It is not clear whether the reported HLA alleles are responsible for the differences in cervical cancer susceptibility, or if functional variants at other locations within the major histocompatibility complex (MHC) region may explain the effect. In order to assess the relative contribution of both classic HLA alleles and single‐nucleotide polymorphisms (SNPs) within the MHC region to cervical cancer susceptibility, we have imputed classic HLA alleles in 1034 cervical cancer patients and 3948 controls in a Swedish population for an integrated analysis. We found that the protective haplotype DRB1*1301‐DQA1*0103‐DQB1*0603 has a direct effect on cervical cancer and always occurs together with the C allele of a HLA‐DRB1 cis‐eQTL (rs9272143), which increases the expression of HLA‐DRB1. The haplotype rs9272143C‐DRB1*1301‐DQA1*0103‐DQB1*0603 conferred the strongest protection against cervical cancer (odds ratio [OR] = 0.41, 95% confidence interval [CI] = 0.32–0.52, P = 6.2 × 10−13). On the other hand, the associations with HLA‐B*0702 and DRB1*1501‐DQB1*0602 are attributable to the joint effects of both the HLA‐DRB1 cis‐eQTL (rs9272143) and a frameshift mutation (G inserion of rs67841474, also known as A5.1) of the MHC class I polypeptide‐related sequence A gene (MICA). Variation in LD between the classic HLA loci, rs9272143 and rs67841474 between populations may explain the different associations of HLA‐B*07 and DRB1*1501‐DQB1*0602 with cervical cancer between studies. The mechanism suggested may also explain similar inconsistent results for other HLA‐associated diseases.
- Open Access
- 7 January 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (1) , 190-198
A variant upstream of HLA‐DRB1 and multiple variants in MICA influence susceptibility to cervical cancer in a Swedish population
In a genome‐wide association study, we have previously identified and performed the initial replication of three novel susceptibility loci for cervical cancer: rs9272143 upstream of HLA‐DRB1, rs2516448 adjacent to MHC class I polypeptide‐related sequence A gene (MICA), and rs3117027 at HLA‐DPB2. The risk allele T of rs2516448 is in perfect linkage disequilibrium with a frameshift mutation (A5.1) in MICA exon 5, which results in a truncated protein. To validate these associations in an independent study and extend our prior work to MICA exon 5, we genotyped the single‐nucleotide polymorphisms at rs9272143, rs2516448, rs3117027 and the MICA exon 5 microsatellite in a nested case–control study of 961 cervical cancer patients (827 carcinoma in situ and 134 invasive carcinoma) and 1725 controls from northern Sweden. The C allele of rs9272143 conferred protection against cervical cancer (odds ratio [OR] = 0.73, 95% confidence interval [CI] = 0.65–0.82; P = 1.6 × 10−7), which is associated with higher expression level of HLA‐DRB1, whereas the T allele of rs2516448 increased the susceptibility to cervical cancer (OR = 1.33, 95% CI = 1.19–1.49; P = 5.8 × 10−7), with the same association shown with MICA‐A5.1. The direction and the magnitude of these associations were consistent with our previous findings. We also identified protective effects of the MICA‐A4 (OR = 0.80, 95% CI = 0.68–0.94; P = 6.7 × 10−3) and MICA‐A5 (OR = 0.60, 95% CI = 0.50–0.72; P = 3.0 × 10−8) alleles. The associations with these variants are unlikely to be driven by the nearby human leukocyte antigen (HLA) alleles. No association was observed between rs3117027 and risk of cervical cancer. Our results support the role of HLA‐DRB1 and MICA in the pathogenesis of cervical cancer.
- 7 January 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (1) , 190-198
Open AccessA variant upstream of HLA‐DRB1 and multiple variants in MICA influence susceptibility to cervical cancer in a Swedish population
In a genome‐wide association study, we have previously identified and performed the initial replication of three novel susceptibility loci for cervical cancer: rs9272143 upstream of HLA‐DRB1, rs2516448 adjacent to MHC class I polypeptide‐related sequence A gene (MICA), and rs3117027 at HLA‐DPB2. The risk allele T of rs2516448 is in perfect linkage disequilibrium with a frameshift mutation (A5.1) in MICA exon 5, which results in a truncated protein. To validate these associations in an independent study and extend our prior work to MICA exon 5, we genotyped the single‐nucleotide polymorphisms at rs9272143, rs2516448, rs3117027 and the MICA exon 5 microsatellite in a nested case–control study of 961 cervical cancer patients (827 carcinoma in situ and 134 invasive carcinoma) and 1725 controls from northern Sweden. The C allele of rs9272143 conferred protection against cervical cancer (odds ratio [OR] = 0.73, 95% confidence interval [CI] = 0.65–0.82; P = 1.6 × 10−7), which is associated with higher expression level of HLA‐DRB1, whereas the T allele of rs2516448 increased the susceptibility to cervical cancer (OR = 1.33, 95% CI = 1.19–1.49; P = 5.8 × 10−7), with the same association shown with MICA‐A5.1. The direction and the magnitude of these associations were consistent with our previous findings. We also identified protective effects of the MICA‐A4 (OR = 0.80, 95% CI = 0.68–0.94; P = 6.7 × 10−3) and MICA‐A5 (OR = 0.60, 95% CI = 0.50–0.72; P = 3.0 × 10−8) alleles. The associations with these variants are unlikely to be driven by the nearby human leukocyte antigen (HLA) alleles. No association was observed between rs3117027 and risk of cervical cancer. Our results support the role of HLA‐DRB1 and MICA in the pathogenesis of cervical cancer.